These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The true composition of kidney stones passed during triamterene therapy. Sörgel F; Ettinger B; Benet LZ J Urol; 1985 Nov; 134(5):871-3. PubMed ID: 4057369 [TBL] [Abstract][Full Text] [Related]
23. Excretion of triamterene and its metabolite in triamterene stone patients. Ettinger B J Clin Pharmacol; 1985; 25(5):365-8. PubMed ID: 4031113 [TBL] [Abstract][Full Text] [Related]
24. Risk of kidney stones. Ettinger B JAMA; 1982 Oct; 248(16):1971. PubMed ID: 7120618 [No Abstract] [Full Text] [Related]
25. Triamterene urolithiasis: solubility, pk, effect on crystal formation, and matrix binding of triamterene and its metabolites. Werness PG; Bergert JH; Smith LH J Lab Clin Med; 1982 Feb; 99(2):254-62. PubMed ID: 7061920 [TBL] [Abstract][Full Text] [Related]
29. Megaloblastic anaemia in an elderly patient treated with triamterene. Joosten E; Pelemans W Neth J Med; 1991 Jun; 38(5-6):209-11. PubMed ID: 1922593 [TBL] [Abstract][Full Text] [Related]
30. Triamterene and the kidney. Sica DA; Gehr TW Nephron; 1989; 51(4):454-61. PubMed ID: 2662034 [TBL] [Abstract][Full Text] [Related]
31. [Treatment of hypertension with bupranolol, bemetizide and triamterene]. Lederle RM; Klaus D Dtsch Med Wochenschr; 1982 Oct; 107(42):1587-91. PubMed ID: 7128471 [No Abstract] [Full Text] [Related]
33. [Hypotensive effects of fursemide, triamterene and reserpine combination in patients with essential hypertension on ambulatory care]. Saldanha RV; Veras RO; de Paula e Silva P; de Serro-Azul LG Rev Paul Med; 1971 Nov; 78(4):137-40. PubMed ID: 5164638 [No Abstract] [Full Text] [Related]
34. A comparison of a hydrochlorothiazide plus triamterene combination (Dyazide) and atenolol in the treatment of patients with mild hypertension: a multicentre study in general practice. Philip IG; Qureshi SM; Richards HH; Sharma SK; Wright FG; Young PH; Rowley-Jones D Br J Clin Pract; 1987 Oct; 41(10):947-53. PubMed ID: 3333144 [No Abstract] [Full Text] [Related]
35. Drug-induced renal stones: incidence, clinical expression and stone analysis. Rapado A; Traba ML; Caycho C; Cifuentes-Delatte L Contrib Nephrol; 1987; 58():25-9. PubMed ID: 2826078 [No Abstract] [Full Text] [Related]
36. Treatment of mild-to-moderate hypertension: comparison between a calcium-channel blocker and a potassium-sparing diuretic. Boulet AP; Chockalingam A; Fodor JG; Laplante L; Houde M; Lenis J; Logan AG; Robitaille MN; Ryan D; Spénard J J Cardiovasc Pharmacol; 1991; 18 Suppl 9():S45-50. PubMed ID: 1725543 [TBL] [Abstract][Full Text] [Related]
37. [Pharmacology of potassium-sparing diuretics: amiloride and triamterene]. Rorive G; Bovy P Coeur Med Interne; 1978; 17(2):207-15. PubMed ID: 350481 [No Abstract] [Full Text] [Related]